国际皮肤性病学杂志    2005 31 (2): 99-101   ISSN: 2096-5540  CN: 32-1880/R   几种血管活性因子与银屑病 张友灿, 李春阳 山东大学齐鲁医院皮肤科 济南 250012 收稿日期 2004-06-15  修回日期 null  网络版发布日期 null 参考文献  [1] Lowe PM, Lee ML, Jackson CJ, et al. The endothelium in psoriasis. Br J Dermatol, 1995, 132:497-505. [2] Creamer D, Allen MH, Sousa A,et al. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol, 1997, 136:859-865. [3] Tsuboi R, Sato C, Shi CM,et al. Endothelin-1 acts as an autocrine growth factor for normal human keratinocytes. J Cell Physiol, 1994, 159:213-220. [4] Cecchi R, Giomi A, Ciuti M, et al. Increased levels of plasma endothelin-1 in patients with psoriasis. Clin Chim Acta, 1994, 226:113-115. [5] Bonifati C, Mussi A, Carducci M, et al. Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venereol, 1998, 78:22-26. [6] Salani D, Taraboletti G, Rosano L,et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol, 2000, 157:1703-1711. [7] Rossi A, Catani MV, Candi E, et al. Nitric oxide inhibits cornified envelope formation in human keratinocytes by inactivating transglutaminases and activating protein 1. J Invest Dermatol, 2000, 115:731. [8] Bruch-Gerharz D, Schnorr O, Suschek C, et al. Arginase 1 overexpression in psoriasis: limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferation. Am J Pathol, 2003, 162:203-211. [9] Frank S, Stallmeyer B, Kampfer H, et al. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J, 1999, 13:2002-2014. [10] Ormerod AD, Copeland P, Shah SA. Treatment of psoriasis with topical NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis. Br J Dermatol, 2000, 142:985-990. [11] Weller R. Nitric oxide-a newly discovered chemical transmitter in human skin. Br J Dermatol, 1997, 137:665-672. [12] Dvorak AM, Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem, 2001, 49:419-432. [13] Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med, 1994, 180:1141-1146. [14] Nielsen HJ, Christensen IJ, Svendsen MN, et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res, 2002, 51:563-567. [15] Creamer D, Allen M, Jaggar R, et al. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol, 2002, 138:791-796. [16] Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood, 2003, 102:161-168. [17] Jiang WY, Raychaudhuri SP, Farber EM. Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. Int J Dermatol, 1998, 37:572-574. [18] He Y, Ding G, Wang X, et al. Calcitonin gene-related peptide in Langerhans cells in psoriatic plaque lesions. Chin Med J (Engl), 2000, 113:747-751. [19] Carucci JA, Ignatius R, Wei Y,et al. Calcitonin gene-related peptide decreases expression of HLA-DR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell-proliferative responses via the type I calcitonin gene-related peptide receptor. J Immunol, 2000, 164:3494-3499. 通讯作者: